After the Lykos debacle, what’s next for psychedelic therapies?
While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the sector.
Latest edition: 16 September 2024
Latest edition: 16 September 2024
While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the sector.
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
The company plans to focus its resources on conducting clinical trials for CD388 influenza prevention therapy.
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.
The authorisation enables a twice-yearly, ten-minute subcutaneous injection to treat RMS and PPMS.
The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.